vTv Therapeutics (VTVT) Non-Current Deffered Revenue (2017 - 2026)

vTv Therapeutics (VTVT) has 10 years of Non-Current Deffered Revenue data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 90.2% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 90.2% YoY), and the FY2025 full-year result was $18.7 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue slipped to $1.8 million in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $18.7 million in Q2 2022 to a low of $1.8 million in Q1 2026.
• A 5-year average of $17.6 million and a median of $18.7 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 207333.33% in 2022 and sank 90.2% in 2026, its largest moves.
• Tracing VTVT's Non-Current Deffered Revenue over 5 years: stood at $18.7 million in 2022, then changed by 0.0% to $18.7 million in 2023, then changed by 0.0% to $18.7 million in 2024, then changed by 0.0% to $18.7 million in 2025, then slumped by 90.2% to $1.8 million in 2026.
• Business Quant data shows VTVT's Non-Current Deffered Revenue at $1.8 million in Q1 2026, $18.7 million in Q4 2025, and $18.7 million in Q3 2025.